Skip to content Skip to footer
Subscribe Now
NEWS

Novartis to Acquire Tourmaline Bio for ~$1.4B, Complementing its Cardiovascular Portfolio

Shots:Novartis has entered into an agreement to acquire Tourmaline Bio, incl. its asset pacibekitug, expanding its cardiovascular portfolioAs per the deal, Novartis, through its subsidiary, will acquire Tourmaline for $48/share, representing an aggregate of ~$1.4B, & will merge the subsidiary into Tourmaline upon completion, making it an indirect wholly owned unit of Novartis; closing…
September 9, 2025

Read more

Marea Therapeutics
NEWS

Marea Therapeutics Reports First Patient Dosing in P-IIb (TYDAL-TIMI 78) Trial of MAR001 for Atherosclerotic Cardiovascular Disease

Shots:Marea Therapeutics has dosed its first patient with MAR001 in P-IIb (TYDAL-TIMI 78) trial for adults at increased risk of atherosclerotic cardiovascular disease (ASCVD)Trial will evaluate MAR001 (300, 450, 900mg; Q4W) vs PBO in ~216 adults with elevated triglycerides & remnant cholesterol at high ASCVD risk, with the 1EP assessing % change from…
August 7, 2025

Read more

VIEWPOINTS_Curtis Rambaran_2023
VIEWPOINTS

Curtis Rambaran’s Insights from Zerlasiran P-II Study for Patients with Elevated Lipoprotein (a) at High-Risk ASCVD Events

Shots:Curtis gave a brief introduction about Zerlasiran. He also talked about the study design and the results from the P-II trial (ALPACAR-360) under which Zerlasiran is being evaluatedHe also highlighted how Zerlasiran can differ from other therapies that are in development to treat elevated lipoprotein (a) at high risk of atherosclerotic cardiovascular disease (ASCVD)…
August 28, 2023

Read more